Retrieve available abstracts of 10 articles: HTML format
Single Articles
September 2025
ABUSHAKRA S, Power A, Watson D, Porsteinsson A, et al Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in
APOEepsilon4/epsilon4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III,
Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial.
Drugs. 2025 Sep 28. doi: 10.1007/s40265-025-02250. PubMedAbstract available
SMOLLER C, Schiller E, Yamashita K, Silverglate BD, et al Current and Emerging Pharmacological Approaches to Agitation in Alzheimer's
Disease: A Narrative Review of New and Repurposed Therapies.
Drugs. 2025 Sep 6. doi: 10.1007/s40265-025-02227. PubMedAbstract available
January 2025
SYED YY Xanomeline/Trospium Chloride: First Approval.
Drugs. 2025;85:103-109. PubMedAbstract available
October 2024
CARPI M, Mercuri NB, Liguori C Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's
Disease and Associated Sleep Disorders.
Drugs. 2024 Oct 4. doi: 10.1007/s40265-024-02096. PubMedAbstract available
KANG C Donanemab: First Approval.
Drugs. 2024;84:1313-1318. PubMedAbstract available
June 2024
HEY JA, Yu JY, Abushakra S, Schaefer JF, et al Analysis of Cerebrospinal Fluid, Plasma beta-Amyloid Biomarkers, and Cognition from
a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4
Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology
Model.
Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02068. PubMedAbstract available
HEY JA, Abushakra S, Blennow K, Reiman EM, et al Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal
Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in
APOE4 Carriers with Early Alzheimer's Disease.
Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02067. PubMedAbstract available
September 2023
CUMMINGS JL, Osse AML, Kinney JW Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease
Modification.
Drugs. 2023 Sep 20. doi: 10.1007/s40265-023-01938. PubMedAbstract available
April 2023
CUMMINGS J Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine
Alzheimer's Disease Therapeutics.
Drugs. 2023 Apr 15. doi: 10.1007/s40265-023-01858. PubMedAbstract available
March 2023
HOY SM Lecanemab: First Approval.
Drugs. 2023;83:359-365. PubMedAbstract available